Table 3.
Overview ongoing trials.
| Identifying number (status) | Phase | Description |
|---|---|---|
| TKI ± CHEMOTHERAPY | ||
| NCT01746277 (recruiting) | II | Chemotherapy (docetaxel or pemetrexed) sequenced by or combined with gefitinib after progression |
| NCT01928160 (not yet recruiting) | II | Chemotherapy (pemetrexed and carboplatin or cisplatin) with or without erlotinib hydrochloride in treating patient with stage IV non-small cell lung cancer resistant to first-line therapy with erlotinib hydrochloride or gefitinib |
| NCT02098954 (not yet recruiting) | II | Erlotinib combined with chemotherapy (gemcitabine) in TKI-resistant non-small cell lung cancers |
| NCT01998061 (recruiting) | II | Continuation of TKI with or without chemotherapy beyond gradual progression |
| NCT02064491 (recruiting) | II | Erlotinib treatment with or without chemotherapy beyond progression in EGFR-mutant NSCLC |
| LOCAL THERAPY | ||
| NCT01573702 (recruiting) | II | Stereotactic radiosurgery or other local ablation followed by erlotinib for patients with epidermal growth factor receptor (EGFR) mutation who have previously progressed on an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) |
| ALTERNATIVE DOSING OR SWITCH TO NEXT-GENERATION TKI | ||
| NCT01530334 (ongoing) | II | Iressa re-challenge in advanced NSCLC EGFR M+ patients who responded to gefitinib used as 1st line or previous treatment (ICARUS) |
| NCT01932229 (recruiting) | II | An open label study of BIBW 2992/afatinib in advanced non-small cell lung cancer patients pre-treated with erlotinib or gefitinib |
| NCT01526928 (recruiting) | I/II | CO-1686 (third-generation TKI) in second or third-line treatment for EGFR positive NSCLC, with disease progression under first or second-generation TKI |
| COMBINATION THERAPY | ||
| NCT01982955 (recruiting) | I/II | MSC2156119J in combination with gefitinib in subjects with MET positive locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutation and having acquired resistance to first-line gefitinib |
| NCT01610336 (recruiting) | I/II | INC280 administered orally in combination with gefitinib in adult patients with EGFR mutated, c-MET-amplified non-small cell lung cancer who have progressed after EGFR inhibitor treatment |
| NCT01900652 (recruiting) | II | A study of LY2875358 in non-small cell lung cancer participants |
| NCT01090011 (ongoing) | I | BIBW 2992 (afatinib) plus cetuximab (Erbitux®) in patients with non-small cell lung cancer with progression following prior erlotinib (Tarceva®) or gefitinib (Iressa®) |
| NCT01259089 (ongoing) | I/II | Hsp90 inhibitor AUY922 and erlotinib hydrochloride in treating patients with stage IIIB-IV non-small cell lung cancer |
| NCT01646125 (recruiting) | II | An open label, randomized phase II study to evaluate the efficacy of AUY922 vs. pemetrexed or docetaxel in NSCLC patients with EGFR mutations |